Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder

Archives of General Psychiatry

Volumn 69, Issue 9, 2012, Pages 952-961

  Schulz, Kurt P ^a   Fan, Jin ^a,b   Bédard, Anne Claude V ^a   Clerkin, Suzanne M ^a   Ivanov, Iliyan ^a   Tang, Cheuk Y ^a   Halperin, Jeffrey M ^a,b   Newcorn, Jeffrey H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ADOLESCENT; ANTERIOR CINGULATE; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFERIOR FRONTAL GYRUS; MALE; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT; POSTERIOR CINGULATE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STIMULUS RESPONSE; SYMPTOM; TASK PERFORMANCE; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEMALE; FRONTAL LOBE; GYRUS CINGULI; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MALE; METHYLPHENIDATE; MOTOR CORTEX; NEURAL PATHWAYS; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; PROPYLAMINES; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

EID: 84866045828     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.2053     Document Type: Article

References (65)

1. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008;42(1):24-31.
2. Gatley SJ, Pan D, Chen R, Chaturvedi G, Ding YS. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci. 1996;58(12):231-239.
3. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52(12):1023-1029.
4. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D; Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721-730.
5. Chamberlain SR, Hampshire A, Müller U, Rubia K, Del Campo N, Craig K, Regenthal R, Suckling J, Roiser JP, Grant JE, Bullmore ET, Robbins TW, Sahakian BJ. Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry. 2009;65(7):550-555.
6. Rubia K, Halari R, Cubillo A, Smith AB, Mohammad AM, Brammer M, Taylor E. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naive boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology. 2011;36(8):1575-1586.
7. Epstein JN, Casey BJ, Tonev ST, Davidson MC, Reiss AL, Garrett A, Hinshaw SP, Greenhill LL, Glover G, Shafritz KM, Vitolo A, Kotler LA, Jarrett MA, Spicer J. ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD. J Child Psychol Psychiatry. 2007;48(9):899-913.
8. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabrieli JD. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A. 1998; 95(24):14494-14499.
9. Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1011-1023.
10. Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science. 2006;311(5762):861-863.
11. Marquand AF, De Simoni S, O'Daly OG, Williams SC, Mourão-Miranda J, Mehta MA. Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers. Neuropsychopharmacology. 2011;36(6):1237-1247.
12. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
13. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006;60(10):1111-1120.
14. Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;22(2):389-395.
15. Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol. 2001;432(1):119-136.
16. Fassbender C, Zhang H, Buzy WM, Cortes CR, Mizuiri D, Beckett L, Schweitzer JB. A lack of default network suppression is linked to increased distractibility in ADHD. Brain Res. 2009;1273:114-128.
17. Peterson BS, Potenza MN, Wang Z, Zhu H, Martin A, Marsh R, Plessen KJ, Yu S. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry. 2009;166(11):1286-1294.
18. Tomasi D, Volkow ND, Wang GJ, Wang R, Telang F, Caparelli EC, Wong C, Jayne M, Fowler JS. Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls. Neuroimage. 2011;54(4):3101-3110.
19. Seneca N, Gulyás B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl). 2006;188(1):119-127.
20. Sasané R, Hodgkins P, Meijer W. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Curr Med Res Opin. 2010;26(11):2565-2574.
21. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):511-518.
22. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbäumer K, Kung HF, Hahn K, Tatsch K. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med. 2000;27(10):1518-1524.
23. Lee JS, Kim BN, Kang E, Lee DS, Kim YK, Chung JK, Lee MC, Cho SC. Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment. Hum Brain Mapp. 2005;24(3):157-164.
24. Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry. 2004;56(8):597-606.
25. Bush G, Spencer TJ, Holmes J, Shin LM, Valera EM, Seidman LJ, Makris N, Surman C, Aleardi M, Mick E, Biederman J. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Arch Gen Psychiatry. 2008;65(1):102-114.
26. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988.
27. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
28. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proofof-product studies. Arch Gen Psychiatry. 2003;60(2):204-211.
29. Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003;13(1):53-63.
30. Zhang S, Faries DE, Vowles M, Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res. 2005;14(4):186-201.
31. Durston S, Thomas KM, Worden MS, Yang Y, Casey BJ. The effect of preceding context on inhibition: an event-related fMRI study. Neuroimage. 2002;16(2):449-453.
32. Durston S, Tottenham NT, Thomas KM, Davidson MC, Eigsti IM, Yang Y, Ulug AM, Casey BJ. Differential patterns of striatal activation in young children with and without ADHD. Biol Psychiatry. 2003;53(10):871-878.
33. Bédard AC, Schulz KP, Cook EH Jr, Fan J, Clerkin SM, Ivanov I, Halperin JM, Newcorn JH. Dopamine transporter gene variation modulates activation of striatum in youth with ADHD. Neuroimage. 2010;53(3):935-942.
34. Friston KJ, Fletcher P, Josephs O, Holmes A, Rugg MD, Turner R. Event-related fMRI: characterizing differential responses. Neuroimage. 1998;7(1):30-40.
35. Johnstone T, Ores Walsh KS, Greischar LL, Alexander AL, Fox AS, Davidson RJ, Oakes TR. Motion correction and the use of motion covariates in multiple-subject fMRI analysis. Hum Brain Mapp. 2006;27(10):779-788.
36. Hayasaka S, Phan KL, Liberzon I, Worsley KJ, Nichols TE. Nonstationary clustersize inference with random field and permutation methods. Neuroimage. 2004;22(2):676-687.
37. Slotnick SD, Schacter DL. A sensory signature that distinguishes true from false memories. Nat Neurosci. 2004;7(6):664-672.
38. Gilbert DL, Ridel KR, Sallee FR, Zhang J, Lipps TD, Wassermann EM. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology. 2006;31(2):442-449.
39. Buchmann J, Gierow W, Weber S, Hoeppner J, Klauer T, Benecke R, Haessler F, Wolters A. Restoration of disturbed intracortical motor inhibition and facilitation in attention deficit hyperactivity disorder children by methylphenidate. Biol Psychiatry. 2007;62(9):963-969.
40. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010;114(1):259-270.
41. Garavan H, Hester R, Murphy K, Fassbender C, Kelly C. Individual differences in the functional neuroanatomy of inhibitory control. Brain Res. 2006;1105(1):130-142.
42. Xue G, Aron AR, Poldrack RA. Common neural substrates for inhibition of spoken and manual responses. Cereb Cortex. 2008;18(8):1923-1932.
43. Duann JR, Ide JS, Luo X, Li CS. Functional connectivity delineates distinct roles of the inferior frontal cortex and presupplementary motor area in stop signal inhibition. J Neurosci. 2009;29(32):10171-10179.
44. Stevens MC, Kiehl KA, Pearlson GD, Calhoun VD. Functional neural networks underlying response inhibition in adolescents and adults. Behav Brain Res. 2007;181(1):12-22.
45. Chamberlain SR, Robbins TW, Winder-Rhodes S, Müller U, Sahakian BJ, Blackwell AD, Barnett JH. Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery. Biol Psychiatry. 2011;69(12):1192-1203.
46. Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, Sahakian BJ. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2007;62(9):977-984.
47. Paus T. Primate anterior cingulate cortex: where motor control, drive and cognition interface. Nat Rev Neurosci. 2001;2(6):417-424.
48. Dosenbach NU, Fair DA, Miezin FM, Cohen AL, Wenger KK, Dosenbach RA, Fox MD, Snyder AZ, Vincent JL, Raichle ME, Schlaggar BL, Petersen SE. Distinct brain networks for adaptive and stable task control in humans. Proc Natl Acad Sci U S A. 2007;104(26):11073-11078.
49. Schulz KP, Bëdard AC, Czarnecki R, Fan J. Preparatory activity and connectivity in dorsal anterior cingulate cortex for cognitive control. Neuroimage. 2011;57(1):242-250.
50. Aron AR, Poldrack RA. The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1285-1292.
51. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry. 2005;57(11):1273-1284.
52. Milham MP, Banich MT, Claus ED, Cohen NJ. Practice-related effects demonstrate complementary roles of anterior cingulate and prefrontal cortices in attentional control. Neuroimage. 2003;18(2):483-493.
53. Uddin LQ, Kelly AM, Biswal BB, Xavier Castellanos F, Milham MP. Functional connectivity of default mode network components: correlation, anticorrelation, and causality. Hum Brain Mapp. 2009;30(2):625-637.
54. Mason MF, Norton MI, Van Horn JD, Wegner DM, Grafton ST, Macrae CN. Wandering minds: the default network and stimulus-independent thought. Science. 2007;315(5810):393-395.
55. Volkow ND, Fowler JS, Wang GJ, Telang F, Logan J, Wong C, Ma J, Pradhan K, Benveniste H, Swanson JM. Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task. PLoS One. 2008;3(4):e2017.
56. Smith HR, Beveridge TJ, Porrino LJ. Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience. 2006;138(2):703-714.
57. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002;43(3):181-187.
58. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.
59. Bamford NS, Zhang H, Schmitz Y, Wu NP, Cepeda C, Levine MS, Schmauss C, Zakharenko SS, Zablow L, Sulzer D. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron. 2004;42(4):653-663.
60. Chase TD, Brown RE, Carrey N, Wilkinson M. Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats. Neuroreport. 2003;14(5):769-772.
61. Allen JK, Wilkinson M, Soo EC, Hui JP, Chase TD, Carrey N. Chronic low dose Adderall XR down-regulates cfos expression in infantile and prepubertal rat striatum and cortex. Neuroscience. 2010;169(4):1901-1912.
62. Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA. Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007;27(27):7196-7207.
63. Tomasi D, Volkow ND, Wang R, Telang F, Wang GJ, Chang L, Ernst T, Fowler JS. Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. PLoS One. 2009;4(6):e6102.
64. Castellanos FX, Margulies DS, Kelly C, Uddin LQ, Ghaffari M, Kirsch A, Shaw D, Shehzad Z, Di Martino A, Biswal B, Sonuga-Barke EJ, Rotrosen J, Adler LA, Milham MP. Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(3):332-337.
65. Kelly AM, Uddin LQ, Biswal BB, Castellanos FX, Milham MP. Competition between functional brain networks mediates behavioral variability. Neuroimage. 2008;39(1):527-537.